EXTENDED INDUCTION IN THE TRUE NORTH OPEN-LABEL EXTENSION STUDY: CLINICAL OUTCOMES OF ∼2 YEARS OF OZANIMOD TREATMENT

被引：0
|
作者：
Rubin, David T.
Colombel, Jean Frederic
Chiorean, Michael V.
Ghosh, Subrata
Jain, Anjali
Lawlor, Garrett
Osterman, Mark T.
Wu, Hsiuanlin
Canavan, James B.
Vermeire, Severine
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu1736
引用
收藏
页码：S1102 / S1102
页数：1
相关论文
共 50 条
  • [21] An Interim Analysis of 2 Years of Continuous Ozanimod Treatment From the True North OpenLabel Extension Study
    Abreu, Maria
    Dulai, Parambir
    Dignass, Axel
    Savarino, Edoardo
    Hudesman, David
    Afzali, Anita
    Jairath, Vipul
    Osterman, Mark
    Akukwe, Lucy
    Liu, W. Jerry
    Memaj, Arteid
    Petersen, AnnKatrin
    Jain, Anjali
    Canavan, James
    Vermeire, Severine
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 : S20 - S20
  • [22] LONG-TERM SAFETY OF 3 YEARS OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION
    Abreu, Maria T.
    Danese, Silvio
    Wolf, Douglas C.
    Canavan, James B.
    Jain, Anjali
    Wu, Hsiuanlin
    Petersen, AnnKatrin
    Charles, Lorna
    Afzali, Anita
    Panaccione, Remo
    GASTROENTEROLOGY, 2023, 164 (06) : S208 - S208
  • [23] Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension
    Panaccione, R.
    Danese, S.
    Wolf, D. C.
    Canavan, J. B.
    Jain, A.
    Wu, H.
    Petersen, A.
    Charles, L.
    Afzali, A.
    Abreu, M. T.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 534 - 534
  • [24] Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension
    Danese, Silvio
    Panaccione, Remo
    Abreu, Maria T.
    Rubin, David T.
    Ghosh, Subrata
    Dignass, Axel
    Afzali, Anita
    Wolf, Douglas C.
    Chiorean, Michael, V
    Vermeire, Severine
    Jain, Anjali
    Charles, Lorna
    Lawlor, Garrett
    Osterman, Mark T.
    Wu, Hsiuanlin
    Canavan, James B.
    Petersen, Annkatrin
    Colombel, Jean-Frederic
    Regueiro, Miguel
    JOURNAL OF CROHNS & COLITIS, 2024, 18 (02): : 264 - 274
  • [25] Safety of long-term ozanimod treatment for up to 4 years in patients with moderately to severely active Ulcerative Colitis: an interim analysis of the True North open-label extension
    Siegel, C.
    Danese, S.
    Rubin, D. T.
    Sabino, J.
    Long, M. D.
    Cross, R. K.
    Armuzzi, A.
    Blumenstein, I.
    Kobayashi, T.
    Lama, S.
    Charles, L.
    Cetin, V.
    Petersen, A.
    Wu, H.
    Wang, D.
    Jain, A.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I100 - I101
  • [26] Safety of Long-Term Ozanimod Treatment Up to 5 Years in Patients With Moderately to Severely Active Ulcerative Colitis: An Interim Analysis of the True North Open-Label Extension
    Abraham, Bincy P.
    Longman, Randy
    Katsanos, Konstantinos
    Lee, Scott D.
    Kobayashi, Taku
    Bettenworth, Dominik
    Korman, Louis
    Mehra, Dimpy
    Santiago, Norma Ruiz
    Petersen, Annkatrin
    Desai, Manik
    Wu, Hsiuanlin
    Wang, Dong
    Osterman, Mark T.
    Jain, Anjali
    Torres, Joana
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1063 - S1063
  • [27] Serologic Response to SARS-CoV-2 Vaccines in an Ozanimod Open-Label Extension Study
    Caldera, Freddy
    Maddux, Rachel
    Ungaro, Ryan
    Kaur, Amandeep
    Brown, Elizabeth
    Hu, Sarah
    Sheffield, James
    Silva, Diego
    Harris, Sarah
    Cree, Bruce
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 : S11 - S12
  • [28] Clinical outcomes with evobrutinib in relapsing MS up to 4 years of treatment: an ongoing Phase 2 open-label extension
    Montalban, X.
    Arnold, D.
    Weber, M.
    Piasecka-Stryczynska, K.
    Tomic, D.
    Kinkolykh, A.
    Li, Y.
    Guehring, H.
    Wolinsky, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 248 - 248
  • [29] Humoral immune responses to SARS-CoV-2 vaccines in an ozanimod open-label extension study
    Caldera, F.
    Maddux, R.
    Ungaro, R.
    Kaur, A.
    Brown, E.
    Hu, S.
    Sheffield, J. K.
    Silva, D.
    Harris, S.
    Cree, B. A. C.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 643 - 644
  • [30] Hepatic safety of ozanimod in relapsing multiple sclerosis in the DAYBREAK open-label extension study
    Selmaj, K.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, E. K.
    Sheffield, J. K.
    Minton, N.
    Afsari, S.
    Shi, F.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 608 - 609
12345